Scancell Holdings Plc. said a patent for its DNA ImmunoBody technology has now been granted in Europe.
The platform was used to develop SCIB1 and SCIB2 – the company’s leading drug candidates. The two are designed to help the body’s immune system to fight cancer.
“The addition of this key European patent for DNA ImmunoBody significantly bolsters our global intellectual property portfolio as we position the company for future growth,” said chief executive Richard Goodfellow.
Scancell already has patent protection in the United States, Australia and Japan.